A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow

Blood

Volumn 125, Issue 11, 2015, Pages 1739-1748

  Mei, Henrik E ^a,b,f   Wirries, Ina ^a,b   Frölich, Daniela ^a,b   Brisslert, Mikael ^c   Giesecke, Claudia ^a,b   Grün, Joachim R ^b   Alexander, Tobias ^a,b   Schmidt, Stefanie ^a,b   Luda, Katarzyna ^a,b,e   Kühl, Anja A ^a   Engelmann, Robby ^d   Dürr, Michael ^a   Scheel, Tobias ^b   Bokarewa, Maria ^c   Perka, Carsten ^a   Radbruch, Andreas ^b   Dörner, Thomas ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Leibniz Institute   (Germany)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e LUND UNIVERSITY   (Sweden)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; BORTEZOMIB; CASPASE 3; CASPASE 8; CD19 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD38 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FAS ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; INTERLEUKIN 6; KI 67 ANTIGEN; PROTEIN BCL 2; SYNDECAN 1; BORONIC ACID DERIVATIVE; DIPHTHERIA TETANUS VACCINE; LYMPHOCYTE ANTIBODY; PYRAZINE DERIVATIVE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD; BONE MARROW; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; JOINT BIOPSY; MUTATION RATE; PHENOTYPE; PLASMA CELL; PLASMABLAST; PRIORITY JOURNAL; SPLEEN; TONSIL; VACCINATION; BIOLOGICAL MODEL; BONE MARROW CELL; CELL DIFFERENTIATION; CELL SURVIVAL; CLASSIFICATION; CYTOLOGY; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE DEPLETION; METABOLISM; MUTATION; PATHOLOGY; VDJ RECOMBINATION;

ANTIGENS, CD19; ANTILYMPHOCYTE SERUM; BONE MARROW CELLS; BORONIC ACIDS; CELL DIFFERENTIATION; CELL SURVIVAL; DIPHTHERIA-TETANUS VACCINE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFLAMMATION; LYMPHOCYTE DEPLETION; MODELS, IMMUNOLOGICAL; MUTATION; PHENOTYPE; PLASMA CELLS; PYRAZINES; V(D)J RECOMBINATION;

EID: 84925007424     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-555169     Document Type: Article

References (71)

1. Manz RA, Löhning M, Cassese G, Thiel A, Radbruch A. Survival of long-lived plasma cells is independent of antigen. Int Immunol. 1998;10(11):1703-1711.
2. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature. 1997;388(6638):133-134.
3. Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006;6(10):741-750.
4. Merville P, Déchanet J, Desmoulière A, et al. Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J Exp Med. 1996;183(1):227-236.
5. Yoshida T, Mei H, Dörner T, et al. Memory B and memory plasma cells. Immunol Rev. 2010;237(1):117-139.
6. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903-1915.
7. Haas KM, Tedder TF. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity. Adv Exp Med Biol. 2005;560:125-139.
8. Nutt SL, Morrison AM, Dörfler P, Rolink A, Busslinger M. Identification of BSAP (Pax-5) target genes in early B-cell development by loss-and gain-of-function experiments. EMBO J. 1998;17(8):2319-2333.
9. Kozmik Z, Wang S, Dörfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol. 1992;12(6):2662-2672.
10. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol. 2007;8(5):463-470.
11. Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81(10):2658-2663.
12. Arce S, Luger E, Muehlinghaus G, et al. CD38 low IgG-secreting cells are precursors of various CD38 high-expressing plasma cell populations. J Leukoc Biol. 2004;75(6):1022-1028.
13. Medina F, Segundo C, Campos-Caro A, González-García I, Brieva JA. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood. 2002;99(6):2154-2161.
14. Ellyard JI, Avery DT, Phan TG, Hare NJ, Hodgkin PD, Tangye SG. Antigen-selected, immunoglobulin-secreting cells persist in human spleen and bone marrow. Blood. 2004;103(10):3805-3812.
15. Peceliunas V, Janiulioniene A, Matuzeviciene R, Griskevicius L. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B Clin Cytom. 2011;80(5):318-323.
16. Pellat-Deceunynck C, Bataille R, Robillard N, et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood. 1994;84(8):2597-2603.
17. Mei HE, Yoshida T, Sime W, et al. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood. 2009;113(11):2461-2469.
18. Frölich D, Giesecke C, Mei HE, et al. Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells. J Immunol. 2010;185(5):3103-3110.
19. Mei HE, Frölich D, Giesecke C, et al. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood. 2010;116(24):5181-5190.
20. Trepel F. Number and distribution of lymphocytes in man. A critical analysis. Klin Wochenschr. 1974;52(11):511-515.
21. McMillan R, Longmire RL, Yelenosky R, Lang JE, Heath V, Craddock CG. Immunoglobulin synthesis by human lymphoid tissues: normal bone marrow as a major site of IgG production. J Immunol. 1972;109(6):1386-1394.
22. Benner R, Hijmans W, Haaijman JJ. The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation. Clin Exp Immunol. 1981;46(1):1-8.
23. Odendahl M, Mei H, Hoyer BF, et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood. 2005;105(4):1614-1621.
24. Medina F, Segundo C, Rodríguez C, Brieva JA. Regulatory role of CD95 ligation on human B cells induced in vivo capable of spontaneous and high-rate Ig secretion. Eur J Immunol. 1997;27(3):700-706.
25. Pelletier N, Casamayor-Pallejà M, De Luca K, et al. The endoplasmic reticulum is a key component of the plasma cell death pathway. J Immunol. 2006;176(3):1340-1347.
26. Ursini-Siegel J, Zhang W, Altmeyer A, et al. TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J Immunol. 2002;169(10):5505-5513.
27. Strasser A, Whittingham S, Vaux DL, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA. 1991;88(19):8661-8665.
28. Peperzak V, Vikström I, Walker J, et al. Mcl-1 is essential for the survival of plasma cells. Nat Immunol. 2013;14(3):290-297.
29. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123.
30. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation. 2005;79(11):1507-1515.
31. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67(4):1783-1792.
32. Hauser AE, Debes GF, Arce S, et al. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol. 2002;169(3):1277-1282.
33. Cassese G, Arce S, Hauser AE, et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol. 2003;171(4):1684-1690.
34. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003;9(9):1131-1137.
35. Hoyer BF, Manz RA, Radbruch A, Hiepe F. Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci. 2005;1050:124-133.
36. Cassese G, Lindenau S, de Boer B, et al. Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells. Eur J Immunol. 2001;31(9):2726-2732.
37. Kallies A, Hasbold J, Tarlinton DM, et al. Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J Exp Med. 2004;200(8):967-977.
38. Kozbor D, Moretta A, Messner HA, Moretta L, Croce CM. Tp44 molecules involved in antigen-independent T cell activation are expressed on human plasma cells. J Immunol. 1987;138(12):4128-4132.
39. Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity. 2006;24(3):269-281.
40. Njau MN, Kim JH, Chappell CP, et al. CD28-B7 interaction modulates short- and long-lived plasma cell function. J Immunol. 2012;189(6):2758-2767.
41. Rozanski CH, Arens R, Carlson LM, et al. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med. 2011;208(7):1435-1446.
42. Njau MN, Jacob J. The CD28/B7 pathway: a novel regulator of plasma cell function. Adv Exp Med Biol. 2013;785:67-75.
43. Nair JR, Carlson LM, Koorella C, et al. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol. 2011;187(3):1243-1253.
44. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol. 2002;169(8):4213-4221.
45. Zehentmeier S, Roth K, Cseresnyes Z, et al. Static and dynamic components synergize to form a stable survival niche for bone marrow plasma cells. Eur J Immunol. 2014;44(8):2306-2317.
46. Rodriguez Gomez M, Talke Y, Goebel N, Hermann F, Reich B, Mack M. Basophils support the survival of plasma cells in mice. J Immunol. 2010;185(12):7180-7185.
47. Chu VT, Fröhlich A, Steinhauser G, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol. 2011;12(2):151-159.
48. Winter O, Moser K, Mohr E, et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood. 2010;116(11):1867-1875.
49. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol. 2002;160(4):1293-1299.
50. Barillé S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood. 1995;86(8):3151-3159.
51. Battula VL, Treml S, Bareiss PM, et al. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica. 2009;94(2):173-184.
52. Mariotti E, Mirabelli P, Abate G, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow and placenta: CD10, CD49d, and CD56 make a difference. Stem Cells Dev. 2008;17(6):1039-1041.
53. Rawstron A, Barrans S, Blythe D, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol. 1999;104(1):138-143.
54. Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma. 2006;47(1):43-47.
55. Rafei M, Hsieh J, Fortier S, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood. 2008;112(13):4991-4998.
56. Ahuja A, Anderson SM, Khalil A, Shlomchik MJ. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci USA. 2008;105(12):4802-4807.
57. Teng YK, Levarht EW, Hashemi M, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum. 2007;56(12):3909-3918.
58. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48(8):2146-2154.
59. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122(1):62-74.
60. Weller S, Mamani-Matsuda M, Picard C, et al. Somatic diversification in the absence of antigen-driven responses is the hallmark of the IgM+ IgD+ CD27+ B cell repertoire in infants. J Exp Med. 2008;205(6):1331-1342.
61. Klein U, Küppers R, Rajewsky K. Variable region gene analysis of B cell subsets derived from a 4-year-old child: somatically mutated memory B cells accumulate in the peripheral blood already at young age. J Exp Med. 1994;180(4):1383-1393.
62. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011;208(1):181-193.
63. Scheid JF, Mouquet H, Kofer J, Yurasov S, Nussenzweig MC, Wardemann H. Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells. Proc Natl Acad Sci USA. 2011;108(44):18044-18048.
64. Phan TG, Paus D, Chan TD, et al. High affinity germinal center B cells are actively selected into the plasma cell compartment. J Exp Med. 2006;203(11):2419-2424.
65. Zand MS, Vo T, Pellegrin T, et al. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood. 2006;107(7):2895-2903.
66. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748-755.
67. Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):572-577.
68. Mei HE, Schmidt S, Dörner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther. 2012;14(Suppl 5):S1.
69. Van Camp B, Durie BG, Spier C, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood. 1990;76(2):377-382.
70. Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006;108(13):4194-4197.
71. Alapat D, Coviello-Malle J, Owens R, et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol. 2012;137(1):93-100.